NEW DELHI : Bharat Biotech International Ltd’s enrolment of participants in its phase 3 efficacy trial of Covaxin has crossed the halfway mark of 13,000 participants in just about a month after starting its trial, the company said on Tuesday.The Phase 3 human clinical trials of Covaxin began in mid-November, and the company plans to recruit 26,000 volunteers at more than two dozen sites across India for it.
So far, this is India’s first and only Phase 3 efficacy study for a covid-19 vaccine, and the largest phase 3 efficacy trial ever conducted for any vaccine in India.Also Read | Dark underbelly of India Inc’s shop floorsThe company, however, refused to divulge details on how many of the 13,000 participants have received two doses of the.